



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/419,517	10/18/1999	WAYNE H. KAESEMEYER	97-092-US-C2	1371

7590 05/05/2004

Raymond A Miller c/o Pepper Hamilton LLP
500 Grant Street 50th floor
Pittsburgh, PA 15219-2502

EXAMINER

KIM, JENNIFER M

ART UNIT	PAPER NUMBER
----------	--------------

1617

DATE MAILED: 05/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/419,517	KAESEMEYER, WAYNE H.	
	Examiner	Art Unit	
	Jennifer Kim	1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 24 December 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-6, 12, 13 and 16-26 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-6, 12, 13, 16-26 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The response filed on December 24, 2003 have been received and entered into the application.

Action Summary

Claims 20, 21 and 23-26 of record rejected under 35 U.S.C. 112, first Paragraph, New Matter rejection is maintained for the reasons stated in the previous office action.

Claims 20, 21 and 23-26 of record rejected under 35 U.S.C. 102 (e) over Liao et al. (U.S.Patent No. 6,147,109) is maintained for the reasons stated in the previous office action.

Claims 1,2,5,6,12,13,16 and 17 of record rejected under 35 U.S.C. 103 (a) over Morris et al. (1994) is maintained for the reasons stated in the previous office action.

Claims 1-6, 12, 13, 16-19 and 22 of record rejected under 35 U.S.C. 103 (a) over McGovern et al. (U.S.Patent No. 5,634,895) and Igo et al. (U.S.Patent No. 5,634,895) is maintained for the reasons stated in the previous office action.

Claims 1,2,5,12,13,16,17,20 and 21 of record rejected under 35 U.S.C. 103 (a) over Wang et al. (1994), Pharmacol. Res. (1996) and Bocan (U.S.Patent No. 6,093,719) is maintained for the reasons stated in the previous office action.

The rejection of claims under the judicially crated doctrine of obviousness-type double patenting as being unpatentable over claims 1-18 of U.S.Patent No. 5,968,983 is hereby expressly withdrawn in view of the executed terminal disclaimer filed by the Applicant.

Response to Arguments

Applicants' arguments December 24, 2003 have been fully considered but they are not persuasive. Applicants argue that the Board in Sorenson found support for the claimed "binuclear copper complexes of carboxylic acids" based on a disclosure of "an organic compound of copper", and therefore the specific inhibitors of atorvastatin and cerivastatin are implicitly and inherently supported in the application as originally filed. This is not persuasive because the Court states on page 1464, "a binuclear copper complexes of carboxylic acids" a "binuclear copper complex of an aliphatic carboxylic acid", a "binuclear copper complex of an aryl carboxylic acid", that Sorenson provided **structural guidance** of the compounds having "**copper complexes of carboxylic acids**" provided guidance for the subject matter at issue, but **no such structural guidance** was given in instant case, thus Sorenson is not applicable to instant Application. Other words, envisioned **function** (Hmg-CoA reductase inhibitors; inhibit and reduce the intrinsic biosynthesis of cholesterol) does not lead one to the specific compound without the specific structural guidance. Applicants, similarly, argue that the Board reaffirmed the written description in Union Oil Co, that the description recited ranges of chemical properties which work in combination with ranges of other chemical properties to produce an automotive gasoline. This is not persuasive because this case is not applicable to instant application since there was support or the ranges of chemical

Art Unit: 1617

properties, which work in combination with ranges of other chemical properties. However, in instant case there is not support of the specific Hmg-CoA reductase (atorvastatin and cerivastatin) by the parent Application. It is noted that there is no structural relationship and no common core. Therefore, envisioned **function** (Hmg-CoA reductase inhibitors; inhibit and reduce the intrinsic biosynthesis of cholesterol) does not lead one to the specific compound without the support of the specific structural guidance. Applicants argue that the specific list of the inhibitors of HmG-CoA reductase inhibitors were "by way of example only" and atorvastatin and cerivastatin were both implicitly and inherently disclosed in the application as originally filed. This is not persuasive because atorvastatin and cerivastatin are not explicitly disclosed or taught by the original application as filed and there is no literal support of these two agents. Therefore at the time that instant Application was filed, Applicants had no possession of the claimed specific active agents (i.e. atorvastatin and cerivastatin) and an Affidavit under Rule 131 using the prior patent would not serve as a clear evidence of prior conception and reduction to practice. Applicants argue that Applicant's original disclosure predates the filing date of U.S. Patent No. 6,147,109 to Liao since the disclosure of page 9, lines 13-14 of the Application that "L-arginine being used in conjunction with virtually any of the family of those substances known as Hmg-CoA reductase inhibitors". This is not persuasive because as commented above, atorvastatin and cerivastatin are not explicitly disclosed or taught by the original application as filed and there is no literal support of these two agents any where in the Application. Therefore, the Liao patent is applicable and anticipates Applicants' claims.

Art Unit: 1617

Applicants argue that Morris's teaching of an obscure Hmg-CoA reductase inhibitor arginine salt, without any suggestion, motivation or otherwise rationale for using it to treat a disease state in no way anticipates or make obvious the present invention. This is not persuasive because Morris et al. clearly teach a novel Hmg-CoA reductase inhibitor with a suggestion of its optimum salt form (i.e. arginine salt). It is well known that Hmg-CoA reductase inhibitors are known to treat hypercholesterolemia and it is also well admitted by the Applicants (page 1, lines 8-18, DESCRIPTION OF RELATED ART). It is noted that claims 1,2,5,6,12,13 16 and 17 are drawn to any disease conditions therefore, it would have been obvious to one of ordinary skill in the art to employ a novel Hmg-CoA reductase formulated with its optimal salt form as taught by Morris et al in treatment of any disease conditions (i.e. hypercholesterolemia) as well known to be treated with a Hmg-CoA reductase. Applicants argue that the Examiner has shown no suggestion of motivation to combine the elements and no reasonable expectation of success of rejection of claims 1-6, 12,13,16-19 and 22 over U.S.Patent No. 5,634,895 to McGovern et al. and U.S.Patent No. 5,634,895 to Igo et al. This is not persuasive because each of the active agent is taught by the prior art to treat the diseases that are related to coronary heart and cardiovascular conditions (i.e. restenosis and angioplasty). Therefore it would be expected that the combination of components would treat the diseases related to coronary heart or cardiovascular diseases as well. Applicants argue that cerivastatin, atorvastatin and L-arginine are described in the art are not used for the same purpose therefore, these teachings do not satisfy a prima facie case of obviousness. This is not persuasive because all of the

Art Unit: 1617

active agents are involved in inhibiting or preventing atherogenesis condition as taught by the cited references. Therefore, the combination of the each of the components would prevent or inhibit atherogenesis as well. Thus, the claims fail to patentably distinguish over the state of the art as represented by the cited references.

In view of the above Office Action of 6/13/2003 is deemed proper and asserted with full force and effect herein to obviate applicants' claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 20, 21 and 23-26 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The active agents, atorvastatin and cerivastatin in claims 20, 21 and 23-26 lack literal support in the specification as filed. This is a New Matter rejection.

It is suggested to cancel the new matter in the reply to this Office Action.

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

2. Claims 20,21 and 23-26 are rejected under 35 U.S.C. 102(e) as being anticipated by Liao et al.(U.S.Patent No. 6,147,109) of record.

Liao et al. at the abstract, column 9, lines 10- 27(particularly lines 26 and 27), column 10, lines 19-27(particularly line 27), teach applicants method and the therapeutic mixture comprising treating a disease condition in a subject comprising administering a mixture of L-arginine and Hmg-CoA reductase (atorvastatin or cerivastatin).

Since the Applicants' disclosure of atorvastatin and cerivastatin is not taught in the parent Application serial No. 08/833842, the benefit of priority date of the parent Application does not apply in instant rejection.

Therefore Applicant's priority date of above claims is the filing date of instant Application of October 18, 1999.

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1,2, 5, 6, 12, 13, 16 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Morris et al.(1994).

Morris et al. teach on the abstract that the optimal salt form for a novel HMG-CoA reductase inhibitor, BMS-180431 in oral dosage form is the arginine salt.

Morris et al. also on the abstract teach that above salt selection process can be easily adopted in the drug development program and can be completed within 4 to 6 weeks.

The difference between above reference and Applicant's claimed invention is lack of illustrated example of the novel HMG-CoA reductase with arginine salt for treating a disease condition. However, the skilled artisan would be motivated to employ HMG-CoA reductase together with arginine salt for treatment of hypercholesterolemia since the HMG-CoA reductase with arginine salt form is the optimal salt form for the novel HMG-CoA reductase inhibitor, BMS-180431. The skilled artisan would be motivated with reasonable expectation of success to formulate the novel HMG-CoA reductase with arginine salt form in treatment of the disease condition since this salt selection process

Art Unit: 1617

can be easily adopted in the drug development program for its well known effect as taught by Morris et al. As to claims 16 and 17 which claim a method of stimulating NO synthase administering Applicant's active agents said method involves a mechanism of action which is inherent in the treatment of medical disease condition.

Claims 1-6, 12, 13, 16-19 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over McGovern et al.(U.S. Patent No. 5,634,895) and Igo et al.(U.S. Patent No. 5,634,895), all of record.

2. McGovern et al. on the abstract, teaches a method for preventing onset of restenosis after angioplasty employing a HMG-CoA reductase, pravastatin.

3. McGovern et al. on column 1, lines 26-40, reports that lovastatin, HMG-CoA reductase inhibitor reduces restenosis following angioplasty.

4. Igo et al. teaches on the abstract, column 6, lines 41-44, column 7, lines 7-12, a method of treating angioplasty restenosis and **coronary blood vessels** by administering nitric oxide donor agent including L-arginine.

5. The claims differ from the cited references in claiming combination of L-arginine, and HMG-CoA reductase inhibitor, to treat a condition such as restenosis following angioplasty. To employ combinations of L-arginine and HMG-CoA reductase inhibitor to treat a condition such as restenosis following angioplasty would have been obvious because all the components are well known individually for treating restenosis following

Art Unit: 1617

angioplasty. It would be expected that the combination of components would treat restenosis following angioplasty as well.

The motivation for combining the components flows from their individually known common utility (see *In re Kerkhoven*, 205 USPQ 1069(CCPA 1980)). As to claims 16 and 17 which claim a method of stimulating NO synthase administering Applicant's active agents said method involves a mechanism of action which is inherent in the treatment of medical disease condition.

6. The therapeutic amounts of active agents to be used set forth in claims 6 and 17 and formulate prior to administration or mixed together in vivo set forth in claim 5, the route of administration set forth in claim 2, and setting a periodic indicator set forth in claim 19 are all deemed obvious since they are all within the knowledge of the skilled pharmacologist and represent conventional route of administration.

Claims 1,2,5,12, 13, 16, 17, 20 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wang et al.(1994), Pharmacol. Res. (1996)(U) and Bocan (U.S.Patent No.6,093,719) all of record.

7. Wang et al. teaches on the abstract, that the dietary L-arginine prevents **atherogenesis** in the coronary artery of the hypercholesterolemic rabbit.

8. The U reference teaches that cerivastatin interferes major process involved in **atherogenesis**.

9. Bocan on the abstract teaches atorvastatin alone resulting in a less **atherogenic** lipoprotein profile.

Art Unit: 1617

The claims differ from the cited references in claiming combination of L-arginine, and HMG-CoA reductase inhibitor, cerivastatin or atorvastatin to treat a condition such as atherogenesis. To employ combinations of L-arginine and cerivastatin or atorvastatin to treat a condition such as atherogenesis would have been obvious because all the components are well known individually for treating atherogenesis. It would be expected that the combination of components would treat atherogenesis as well. The motivation for combining the components flows from their individually known common utility (see *In re Kerkhoven*, 205 USPQ 1069(CCPA 1980)). As to claims 16 and 17 which claim a method of stimulating NO synthase administering Applicant's active agents said method involves a mechanism of action which is inherent in the treatment of medical disease condition.

None of the claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of


Art Unit: 1617

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Sreenivasan Padmanabhan
Supervisory Examiner
Art Unit 1617

Jmk
April 21, 2004